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BACKGROUND: Recent genome-wide association studies have identiﬁed genetic loci that jointly make a consid-
erable contribution to risk of developing Alzheimer’s disease (AD). Because neuropathological features of AD can be
present several decades before disease onset, we investigated whether effects of polygenic risk are detectable by
neuroimaging in young adults. We hypothesized that higher polygenic risk scores (PRSs) for AD would be associated
with reduced volume of the hippocampus and other limbic and paralimbic areas. We further hypothesized that AD
PRSs would affect the microstructure of ﬁber tracts connecting the hippocampus with other brain areas.
METHODS: We analyzed the association between AD PRSs and brain imaging parameters using T1-weighted
structural (n 5 272) and diffusion-weighted scans (n 5 197).
RESULTS: We found a signiﬁcant association between AD PRSs and left hippocampal volume, with higher risk
associated with lower left hippocampal volume (p 5 .001). This effect remained when the APOE gene was excluded
(p 5 .031), suggesting that the relationship between hippocampal volume and AD is the result of multiple genetic
factors and not exclusively variability in the APOE gene. The diffusion tensor imaging analysis revealed that fractional
anisotropy of the right cingulum was inversely correlated with AD PRSs (p 5 .009). We thus show that polygenic
effects of AD risk variants on brain structure can already be detected in young adults.
CONCLUSIONS: This ﬁnding paves the way for further investigation of the effects of AD risk variants and may
become useful for efforts to combine genotypic and phenotypic data for risk prediction and to enrich future
prevention trials of AD.
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Biohttp://dx.doi.org/10.1016/j.biopsych.2016.02.033Alzheimer’s disease (AD) is the most common neurodegener-
ative disease, affecting about 5% to 7% of the population over
60 years of age (1). Although a small proportion of cases, often
with a younger onset, are caused by autosomal dominant
mutations, the vast majority of cases do not follow Mendelian
heritability. Such sporadic AD is mediated by both environ-
mental and genetic factors, with many genes contributing
different degrees of risk (2). The most highly penetrant
common genetic risk factor for AD is the apolipoprotein E
(APOE) ε4 allele, each copy of which increases AD risk by a
factor of about 3 (3). However, recent genome-wide associa-
tion studies (GWASs) have identiﬁed a further 19 genome-wide
signiﬁcant loci for AD (4–6), which provide new insights into
possible biological mechanisms underlying the neurodegenera-
tive process (7). Individually, the most powerful of these variants
only marginally increase an individual’s risk for developing AD
(1% to 8%) (4). Polygenic risk scores (PRSs), which are based
on the additive effect of multiple loci across the genome, may be
better suited to capture the variance explained by common& 2016 Society of Biological Psychiatry. This is an open access a
CC BY license (http://creativecommons.org/licenses/by/4.0/).
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SEE COMMENTAalleles (8). PRSs based on the most recent GWASs have
considerable predictive utility for AD risk (9).
Structural brain imaging has consistently revealed both
global and local atrophic changes in patients with AD (10)
and is a useful biomarker for preclinical disease (11). Local
atrophy in medial temporal areas, including the hippocampus,
is observed early in the course of the disorder (12,13) and in
patients with mild cognitive impairment (MCI) (14), a clinical
state that may be a precursor to AD (15). Hippocampal atrophy
predicts conversion from MCI to AD (16) and has also been
reported in carriers of rare dominant AD risk variants in the
genes coding for amyloid precursor protein and presenilin 1
(17), as well as carriers of highly penetrant common variants
such as APOE ε4 (18). Indeed, hippocampal volume is already
a key imaging phenotype to identify preclinical stages of AD
(19). Other brain structures showing signiﬁcant atrophy early in
disease progression include other medial temporal lobe
regions including the entorhinal cortex (ERC) (20,21), para-
hippocampal gyrus (PHG) (22), and posterior cingulate gyrusrticle under the
al ISSN: 0006-3223
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Psychiatry(PCG) (23). We therefore focused on early changes in these
structures.
The combination of PRSs and neuroimaging data is likely to
be particularly informative in identifying markers of early risk
for AD (24,25), even before the putative onset of amyloid
accumulation. In the current study, we sought to investigate
the correlation between polygenic risk for AD based on the
largest genetic training dataset available (4) and gray and
white matter structural differences in a healthy young pop-
ulation without any signs of cognitive impairment. So far, the
only studies conducted with AD PRSs have used 24 risk loci
(26) or PRSs derived from a smaller AD GWASs (23,27),
making ours the genetically most powerful study conducted
on this topic to date.
We predicted that the PRSs for AD would be negatively
correlated with hippocampal volume. We were also interested
in exploring the association of cortical thickness of ERC, PHG,
and PCG, due to the involvement of these areas in early AD
(28–30), where we would expect to see a decrease in thick-
ness. In addition to gray matter parameters, we also inves-
tigated the microstructure of the main white matter pathways
connecting our candidate areas to ascertain whether any gray
matter loss would already have impacted on the ﬁber tracts by
way of anterograde or retrograde degeneration. We measured
fractional anisotropy (FA), a measure of white matter micro-
structure derived from diffusion tensor imaging (DTI) (31) in the
main connecting tracts of the hippocampus, the cingulum, and
the fornix. We expected FA to be lower in participants with
higher AD PRSs.
METHODS AND MATERIALS
Participants
Brain scans used in this study were obtained from a repository
of neuroimaging and genetic data obtained between 2009 and
2014 from healthy subjects recruited through a range of
research projects at Cardiff University Brain Research Imaging
Centre, which has received ethical approval from the Cardiff
University School of Psychology. All subjects were screened
for the exclusion of any neuropsychiatric disorders either by
interview or by questionnaires. Participants provided informed
consent for genotyping and use of their imaging data for
genetic imaging analysis. After genotyping and data quality
control standards, 272 individuals with structural T1 data
remained (195 female, 77 male) with an average age at time
of inclusion of 24.8 years (SD 6.9). Tractography data were
available for a subset of 197 participants (138 female, 59 male)
with an average age at time of inclusion of 23.9 years (SD 5.1).
For a subgroup of 87 participants (53 female, 34 male; mean
age 23.9 years [SD 4.4]), data on the Hopkins Verbal Learning
Task were available. This task measures declarative verbal
learning capacity (32) and forms part of the MATRICS Con-
sensus Cognitive Battery.
Genotyping
Genomic DNA was obtained from saliva using Oragene OG-500
saliva kits (DNA Genotek, Inc., Ontario, Canada). Genotyping was
performed using custom Illumina HumanCoreExome-24 Bead-
Chip genotyping arrays, which contain 570,038 genetic variantsBiological Psy(Illumina, Inc., San Diego, CA). Quality control was implemented
in PLINK (33). Individuals were excluded for any of the following
reasons: 1) ambiguous sex (genotypic sex and phenotypic sex
not aligning); 2) cryptic relatedness up to third-degree relatives as
ascertained using identity by descent; 3) genotyping complete-
ness less than 97%; and 4) non-European ethnicity admixture.
The latter was detected as outliers in an iterative EIGENSTRAT
analysis of a linkage-disequilibrium-pruned dataset (34). Single
nucleotide polymorphisms (SNPs) were excluded where the minor
allele frequency was less than 1%, if the call rate was less than
98%, or if the χ2 test for Hardy-Weinberg equilibrium had a p value
less than 1 3 1024. Individuals’ genotypes were imputed using
the prephasing/imputation stepwise approach implemented in
IMPUTE2/SHAPEIT (35,36) and 1000 Genomes (December
2013, release 1000 Genomes haplotypes Phase I integrated
variant set) (37) as the reference dataset. This resulted in a dataset
of 274 individuals with information for 7,413,342 SNPs.
Polygenic Scoring Method
Polygenic score calculations were performed according to the
procedure described by the International Schizophrenia Con-
sortium (38). Training data were from the International
Genomics of Alzheimer’s Project consortium that comprises
17,008 AD cases and 37,154 control subjects (4). These data
are publicly available from http://www.pasteur-lille.fr/en/recher
che/u744/igap/igap_download.php. SNPs were removed from
all analyses if they had a low minor allele frequency (, .01).
Subsequently, the data were pruned for linkage disequilibrium
using the clumping function (- -clump) in PLINK (33) removing
SNPs within 500 kilobase (- -clump-kb) and r2 . .25 (- -clump-
r2) with a more signiﬁcantly associated SNP. We used
the - -score command in PLINK to calculate polygenic scores
(33). Nine different progressive training p value thresholds (39)
were investigated (polygenic threshold [PT] , 1 3 10
28, 1 3
1027, 1 3 1026, 1 3 1025, 1 3 1024, .01, .1, .3, and .5).
Lower PT indicates that SNPs are more signiﬁcantly associ-
ated with AD case status in the training dataset (AD case-
control study) (4).
These polygenic risk scores include the APOE loci on
chromosome 19, the greatest common genetic risk factor for
AD. If a signiﬁcant association was observed between AD
PRSs and brain imaging phenotypes, the data were reana-
lyzed with polygenic scores excluding any SNPs within the
APOE locus (chromosome 19: 45.053–45.73 Mb), to assess if
the association was purely due to variance in APOE.
Magnetic Resonance Imaging Data
Data Acquisition. Magnetic resonance imaging was carried
out in Cardiff University Brain Research Imaging Centre on a GE
Signa HDx 3T scanner (GE Healthcare, Milwaukee, WI). T1-
weighted structural data were acquired using an axial three-
dimensional fast, spoiled gradient recalled sequence with the
following parameters: repetition time/echo time/inversion time 5
8/3/450 ms; ﬂip angle 5 201; 1 mm resolution; ﬁeld of view
ranging from 256 3 192 3 160 mm3 to 256 3 256 3 256 mm3
(anterior–posterior/left–right/superior–inferior), with acquisition
time ranging from approximately 6 minutes to 10 minutes.
DTI data were acquired using a cardiac-gated sequence
with the following parameters; b-values 0 and 1200, repetitionchiatry January 15, 2017; 81:154–161 www.sobp.org/journal 155
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Psychiatrytime 20 seconds (dependent on heart rate); echo time5 90 ms;
60 2.4-mm slices aligned with the anterior commissure-
posterior commissure, zero slice gap; acquisition matrix 96
3 96; ﬁeld of view 5 230 mm; 2.4-mm isotropic resolution.
Data were either acquired from 30 unique diffusion directions
plus 3 b0 images or from a subsample of 30 optimal directions
from an acquired set of 60 directions with the ﬁrst 3 b0 images.
Data Processing. Hippocampal volume, ERC, PHG, PCG
thickness, and intracranial volume (ICV) were determined through
analysis with FreeSurfer (surfer.nmr.mgh.harvard.edu), which has
been validated as a suitable method for hippocampal segmenta-
tion in large samples (40). The resulting output was quality
controlled following a publically available protocol from ENIGMA
(http://enigma.ini.usc.edu/) (41). Whenever a region of interest was
detected as inadequately segmented by XC or SFF, its metric was
declared missing and excluded from analysis. The numbers of
brain regions included in the ﬁnal analysis were hippocampus right
and left (n 5 270), entorhinal cortex left (n 5 257) and right (n 5
268), posterior cingulate gyrus left (n 5 272) and right (n 5 271),
and parahippocampal gyrus left (n 5 259) and right (n 5 271).
DTI data were analyzed using ExploreDTI (42) version 4.8.3
and were corrected for eddy current distortions and subject
motion using an afﬁne registration to the nondiffusion-weighted
images, with appropriate reorienting of the encoding vectors (43).
An echo planar imaging (4) correction was applied, warping the
DTI data to the fast, spoiled gradient recalled images, resulting in
a 1 3 1 3 1 mm3 resolution in the resulting output. A single
diffusion tensor model was ﬁtted to the DTI data (44) to compute
quantitative parameters such as FA.
Subsequently, the damped Richardson Lucy pipeline (45)
was used to perform whole-brain tractography. Termination
criteria were an angle threshold greater than 451 or a drop in
the magnitude of the minimally subtending ﬁber orientation
density function peak below 0.05. Tracts were obtained using
in-house automated tractography software (46). The auto-
mated tractography models for the fornix, cingulum, and
parahippocampal cingulum (PHC) were based on manual
tractography performed by SFF. Each automated tract under-
went quality control through visual inspection and was brought
to manual tractography standards by post hoc removal of any
ﬁber bundles considered spurious, where necessary. Final
numbers of tracts included were fornix n 5 157 and cingulum
and PHC right and left n 5 197. The fornix was deﬁnedFigure 1. (A) Coronal view of fornix ﬁbers. (B) Sagittal view of right cingulum
156 Biological Psychiatry January 15, 2017; 81:154–161 www.sobp.oraccording to Metzler-Baddeley et al. (47); the high levels of
dropout were most probably due to the high curvature of the
tract and proximity to the ventricles. To segment the PHC, the
restricted method was used, which incorporates a NOT gate-
blocking inclusion of all tracts projecting toward the frontal
cortex (48). For an example of the tracts, see Figure 1.
Free water correction was applied (49,50) before extracting
FA values for further analysis. FA values were extracted
using customized MATLAB scripts (The MathWorks, Inc.,
Natick, MA).
Analysis. Regional thickness data determined from T1 scans
were analyzed using hierarchical linear multiple regression in
IBM SPSS statistics 20 (IBM Corp., Armonk, NY), covarying for
age, gender, and ICV. The hippocampal volumes were
adjusted for ICV of each participant with the formula: hippo-
campal volume corrected = hippocampal volume 2 [beta *
(ICV 2 mean ICV across the group studied)] (51). Subse-
quently, they were analyzed using hierarchical linear multiple
regression covarying for age and gender.
The DTI data were also analyzed using hierarchical linear
multiple regression, including FA as the dependent variable
and controlling for independent variables age, gender, and
scan type (30 or downsampled 60 directions).
The p values were then corrected for multiple comparisons
using false discovery rate in statistics package R (52), resulting
in q values. False discovery rate was applied over the regions
of interest studied. Where signiﬁcant results remained after
false discovery rate correction, further analysis was performed
using the PRSs without APOE SNPs.
It is standard practice to compare PRSs over multiple
thresholds (38), and it is difﬁcult to correct for multiple
comparisons due to the highly correlated nature of the thresh-
olds. Permutation testing is a robust way to correct for multiple
comparisons in a dependent sample (53). The Supplement
contains an outline of permutation tests performed on all the
nominally signiﬁcant results.RESULTS
Hippocampal Volume
PRSs correlated negatively with left hippocampal volume
corrected for intracranial volume (R2 5 .039; p 5 .001;ﬁbers. (C) Sagittal view of right parahippocampal cingulum ﬁbers.
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Table 1. The Inﬂuence of Polygenic AD Risk Scores on Brain Structure
Training
PT Value
Hippo-
campus L R2
(p Value)
Hippo-campus
L No APOE R2
(p Value)
Hippo-
campus R
R2 (p Value)
ERC L R2
(p Value)
ERC R R2
(p Value)
PCG L R2
(p Value)
PCG L No
APOE R2
(p Value)
PCG R R2
(p Value)
PHG L R2
(p Value)
PHG R R2
(p Value)
PT , 1 3
1028
.019 (.024)a ,.001 (.966) ,.001 (.795) ,.001 (.742) .009 (.118) .005 (.224) .003 (.391) .002 (.500) .003 (.386) .003 (.393)
PT , 1 3
1027
.020 (.021)a ,.001 (.991) .001 (.683) ,.001 (.869) .009 (.127) .005 (.213) .001 (.550) .002 (.486) .002 (.433) .004 (.325)
PT , 1 3
1026
.023 (.012)a .003 (.409) ,.001 (.814) ,.001 (.833) .006 (.215) .005 (.215) ,.001 (.788) .003 (.362) .002 (.522) .005 (.227)
PT , 1 3
1025
.034 (.002)a,b .019 (.023)a ,.001 (.958) ,.001 (.873) .007 (.173) .006 (.201) .001 (.635) .004 (.287) .001 (.592) .005 (.256)
PT , 1 3
1024
.039 (.001)a,b .017 (.031)a ,.001 (.932) .001 (.620) .009 (.128) .011 (.073) .009 (.112) .007 (.156) .002 (.481) .006 (.212)
PT , .01 .035 (.002)
a,b .022 (.014)a ,.001 (.933) .005 (.257) .007 (.181) .015 (.034)a .012 (.060) .001 (.554) .003 (.406) .012 (.076)
PT , .1 .023 (.012)
a,b .017 (.032)a ,.001 (.863) .004 (.289) .005 (.253) .025 (.006)a,b .023 (.009)a .001 (.645) .010 (.109) .010 (.099)
PT , .3 .022 (.015)
a .017 (.033)a ,.001 (.850) .002 (.512) .006 (.206) .019 (.019)a .017 (.025)a .002 (.488) .009 (.123) .010 (.094)
PT , .5 .021 (.017)
a .016 (.037)a ,.001 (.748) .002 (.530) .009 (.123) .021 (.014)a .019 (.019)a .002 (.483) .012 (.082) .009 (.128)
R2 change and p values for hippocampal volume (left n 5 270; right n 5 270), entorhinal cortex thickness (left n 5 257; right n 5 268), posterior
cingulate gyrus thickness (left n 5 272; right n 5 271), and parahippocampal gyrus thickness (left n 5 259; right n 5 271). The top axis shows the
region of interest, while the vertical axis shows the polygenic threshold.
AD, Alzheimer’s disease; ERC, entorhinal cortex; FDR, false discovery rate; L, left; PCG, posterior cingulate gyrus; PHG, parahippocampal gyrus;
PT, polygenic threshold; R, right.
aNominally signiﬁcant associations (p value , .05).
bDenotes q-FDR corrected ,0.05.
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24) as demonstrated in Table 1.
PRSs calculated at all PTs were nominally associated
with decreased left hippocampal volume, and four of these
survived correction for multiple testing (Table 1). Analysis of
the R2 change showed that the PRSs accounted for an
additional 1.9% to 3.9% of the variance in left hippocampal
volume over the nine thresholds, after removing variance
explained by age and gender, which accounted for 0.5%.Figure 2. Effects of polygenic risk scores on regions of interest before false d
indicating an increase and downward indicating a decrease of volume or thickn
Biological PsyNo such effect was seen in the right hippocampus,
where R2 changed #.001 across the whole range of PRS
thresholds.
Subsequent analysis of hippocampal volume with the
APOE locus removed from PRSs showed that the signiﬁcant
association between AD PRSs and decreased left hippo-
campal volume persisted (R2 5 .022; p 5 .014; PT , .01),
particularly with the more inclusive pTs (Figure 2).iscovery rate correction. Vertical axis denotes the R2 change, with upward
ess of the region of interest.
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PsychiatryEntorhinal Cortex, Posterior Cingulate Gyrus, and
Parahippocampal Gyrus Thickness
No signiﬁcant effects of AD PRSs were seen on the volume of
the ERC or PHG. A small increase in volume was seen in the
left PCG, which was conserved at one threshold (R2 5 .025;
p 5 .006; q 5 0.048; PT , .1), after correction for multiple
comparisons. This effect persisted after removal of the APOE
locus from the PRSs (Table 1).
Tractography Fornix, Cingulum, and PHC
No effect of AD PRSs on FA was found in the fornix or PHC
(Table 2). However, a signiﬁcant effect of AD PRSs on FA of
the right cingulum was found (R2 5 .032; p 5 .009; q 5 0.045;
PT , 1 3 10
24), with a negative association between PRS and
FA at ﬁve thresholds. This effect was conserved for one of
these thresholds (p # .05) when correcting for multiple
comparisons over all ﬁve regions of interest. Subsequent
analysis of cingulum FA, excluding the APOE locus from the
AD PRSs, only showed a signiﬁcant association at one
threshold (R2 5 .019; p 5 .044; PT , 1 3 10
26).
Cognitive Effects
We found no correlation between scores on the Hopkins Verbal
Learning Task and polygenic risk for AD (Supplemental Table S1).
DISCUSSION
As predicted, PRS for AD was associated with lower hippo-
campal volume. While hippocampal volume reductions in
patients are a robust ﬁnding in AD (10,13) and MCI patients
converting to AD undergo greater hippocampal atrophy (16),
previous reports of hippocampal volume effects of genetic risk
variants in healthy subjects have been varied. Some studies
(54–56) found no effect of APOE risk alleles on hippocampal
volume in young participants, while others found a signiﬁcant
difference between young ε4 and ε2 carriers (18). Previously,
right, but not left, hippocampal volume reductions were found
in APOE ε4 risk allele carriers in comparison with ε3 carriers inTable 2. R2 Change and p Values for the Change in FA Correla
Training PT
Value
Fornix R2
(p Value)
Cingulum L R2
(p Value)
Cingulum R
(p Value
PT , 1 3 10
28 ,.001 (.791) .009 (.164) .030 (.011)
PT , 1 3 10
27 ,.001 (.813) .009 (.162) .029 (.013)
PT , 1 3 10
26 ,.001 (.813) .005 (.270) .023 (.026)
PT , 1 3 10
25 ,.001 (.846) .004 (.344) .025 (.020)
PT , 1 3 10
24 ,.001 (.780) .009 (.165) .032 (.009)
PT , .01 ,.001 (.952) .001 (.610) .006 (.273)
PT , .1 ,.001 (.886) .001 (.626) .005 (.305)
PT , .3 ,.001 (.840) .003 (.440) .002 (.493)
PT , .5 ,.001 (.806) .002 (.486) .002 (.471)
Fornix (n 5 157), cingulum left (n 5 197) and right (n 5 197) (with and w
right (n 5 197) are shown here.
AD, Alzheimer’s disease; FA, fractional anisotropy; FDR, false discovery r
PT, polygenic threshold; R, right; SNP, single nucleotide polymorphism.
aNominally signiﬁcant associations (p value , .05).
bAssociations that survive FDR correction.
158 Biological Psychiatry January 15, 2017; 81:154–161 www.sobp.ora middle-aged population (57), whereas we found effects in
the left, but not right, hippocampus. However, most of the
previous literature has reported a slight preponderance of left
compared with right hippocampal changes, particularly in the
preclinical and early stages of AD progression (58), which
would be in line with our ﬁndings.
We may see signiﬁcant effects where others have obtained
mixed results with single locus studies because of the beneﬁts
of using polygenic risk scores. Although the SNPs contributing
to the PRSs have much smaller individual effect sizes than the
APOE locus, cumulatively they explain a large amount of
variance (9).
Although previous reports have implicated the ERC in AD
pathology (20,21), we do not see an effect of AD genetic risk
on ERC thickness. This is consistent with previous studies (39)
that failed to ﬁnd an effect of APOE on ERC thickness in a
healthy middle-aged and older adult population. Conversely,
the small increase in PCG thickness was unexpected because
both manifest AD and genetic risk status have been associ-
ated with thinning of this area (59,60). Replication of this
ﬁnding in future studies would be needed before strong
conclusions can be drawn.
It has been proposed that AD, like many other neuro-
psychiatric disorders, is a disconnection syndrome (61). Con-
nectivity models of pathophysiology can be supported by the
investigation of the microstructural properties of white matter.
Changes in white matter parameters have indeed been
observed in many DTI studies of AD, for example, decreased
FA in the right fornix (10) and the left PHC (62), superior
longitudinal fasciculus, temporal lobe (63,64), and cingulum
(65). A signiﬁcant decrease of FA was also found in the PHC in
MCI patients (66). Differences in FA relating to AD risk genes
have previously been observed in healthy participants as well;
APOE ε4 was linked to alterations in FA in the left medial
temporal lobe and in the corpus callosum in healthy individuals
(67). One study found widespread FA decreases in a young
healthy population (age 20–35) with APOE risk variants (68),
while another found widespread decreases in FA, including in
the fornix and cingulum, in young individuals carrying theting With AD PRS for Each Threshold
R2
)
Cingulum R No
APOE R2
(p Value)
PHC L R2
(p Value)
PHC R R2
(p Value)
a .006 (.254) .008 (.194) .002 (.534)
a .006 (.268) .006 (.233) .002 (.515)
a .019 (.044)a .006 (.255) .002 (.538)
a .006 (.270) .005 (.292) .001 (.655)
a,b ,.001 (.885) .002 (.547) ,.001 (.949)
,.001 (.858) .003 (.432) .001 (.727)
.001 (.588) .005 (.289) .006 (.268)
,.001 (.777) .003 (.388) .004 (.357)
.001 (.731) .003 (.387) .007 (.240)
ithout APOE SNPs), and parahippocampal cingulum left (n 5 197) and
ate; L, left; PRS, polygenic risk score; PHC, parahippocampal cingulum;
g/journal
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with an autosomal dominant AD variant also had signiﬁcantly
lower FA in the columns of the fornix (70).
Our ﬁnding of reduced FA in the right cingulum, which was
not exclusively driven by the APOE locus, is in line with models
that assume early white matter changes in the course of the
development of AD pathology. The fact that this correlation
between cingulum FA and AD PRSs was not driven by the
PHC, which connects the medial temporal lobe with areas in
the parietal and occipital lobes such as the posterior cingulate
cortex (47), was contrary to expectations. In our sample, the
white matter ﬁndings were not directly related to the gray
matter structural differences that occurred in the opposite
hemisphere.
We used the results from the largest AD GWASs under-
taken to date as our training data (4). Therefore, the estimates
of SNP effects on AD risk utilized in this study are the best
reported to date with better power than previous estimates, as
it is known that polygenic risk score and R2 values are highly
affected by the sample size of the training dataset (71).
Hippocampal volume and cortical thickness are highly
heritable, which makes them appropriate parameters for
genetic imaging analysis (72,73). A limitation of our study is
that, by the nature of the polygenic analysis, which pools risk
variants across the whole genome, no inferences can be made
on the speciﬁc molecular mechanisms contributing to the
structural brain differences. Although neuroﬁbrillary tangles
can be present in the hippocampus in young adults, the Braak
staging model would suggest that entorhinal/transentorhinal
cortex is affected even earlier by this process (74,75). Although
amyloid pathology can be detected in young carriers of
Mendelian variants affecting the amyloid pathway (76), it would
be unlikely to be conﬁned to the hippocampus (75), and our
sample was probably too young to have a signiﬁcant amyloid
load (77). GWASs for AD have revealed novel pathways
associated with AD, including in lipid metabolism, immune
responses, and endocytosis, while also ﬁnding no enrichment
of genes associated with either tau or amyloid pathways,
suggesting other factors may play a role in risk and develop-
ment of AD (7). Furthermore, it is possible that the cumulative
effect of common AD risk variants affects the development of
the hippocampus in a similar way, as they have been shown to
affect cognition across the life course of an individual (78).
Longitudinal studies of genetic imaging, involving even
younger populations than that of the present study, and
pathway-based analysis (79–81) will be needed to address
the biological signiﬁcance of our ﬁndings. However, pathway-
based analyses will likely require larger samples and new
approaches to the multiple testing problem.
In conclusion, AD polygenic risk was associated with
smaller volume of the left hippocampus, increased volume of
left PCG, and lower FA in the right cingulum bundle in healthy
young adults. Thus, AD genetic risk can be linked to structural
differences in brain areas that have been implicated in the
early stages of AD pathology many decades before potential
illness onset. This effect was not driven exclusively by con-
tributions from APOE, as the associations persisted after
removal of the APOE locus. Overall, this work suggests that
genetic risk for AD is mediated, in part, through brain
morphological differences, mainly in the hippocampus,Biological Psyconﬁrming hippocampal volume changes as an important
early biomarker of risk for AD.
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